Journal of Bioequivalence & Bioavailability

The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand

Biography

Dr. Lalinthip Saeaue currently works in the Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand. His research interest includes Bioequivalence; Pharmacokinetics; LC-MS/MS

Publications

• Research   
  Bioequivalence Study of Favipiravir 200 mg Tablets in Healthy Thai Volunteers under Fasting Conditions
  Author(s): Ekawan Yoosakul, Anas Sunhem, Vipada Khaowroongrueng*, Lalinthip Saeaue, Busarat Karachot, Isariya Techatanawat, Porranee Puranajoti and Praphassorn Surawattanawan
  
  Favipiravir is a broad spectrum antiviral against RNA viruses. It has been considered as a promising treatment strategy for a pandemic of Coronavirus Disease 2019 (COVID-19). During this urgent need, the Government Pharmaceutical Organization (GPO), Thailand had developed favipiravir 200 mg tablet formulation (FAVIR®). A randomized, two-treatment, two-period, two-sequence, single-dose, crossover study was designed to determine the bioequivalence of two favipiravir 200 mg tablet formulations, FAVIR® and AVIGAN® under fasting conditions. The plasma-concentration time profiles were used to characterize the rate and extent of absorption of favipiravir in the test and reference products. The pharmacokinetics parameters were calculated using non-compartmental model. The analysis of variance did not show any significant differ.. View more»
  

  DOI: 10.35248/0975-0851.21.13.436

  Abstract HTML PDF